Clinical References

1 American College of Clinical Pharmacology. Pharmacogenomics: Ap- plication to Patient Care. AACP, Kansas City, Mo: ACCP; 2004: 262, 263, 290

2 FDA Drug Safety Communication: Reduced Effectiveness of Plavix (clopidogrel) in Patients Who Are Poor Metabolizers of the Drug; http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncement/ucm204253.

3 Mega JL et al. Cytochrome p-450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2009: Jan 22;360(4): 354-362.

4 Frueh FW, Amur S, Mummaneni et al. Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug Use. Pharmacotherapy. 2008;38: 992-998.

5 Fanikos, John et al. Major Bleeding Complications in a Specialized Anticoagulation Service. Amer J of Cardiology. 2005;96: 595-598.

6 Hansten PD, Hom JR. The Top 100 Drug Interactions. Edmonds, WA: H&H Publications; 2005; 11-13, 26-27, 47-48, 65.

7 Grody W, Griffin J, Taylor A, Korf B, Heit J. American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing. Genetics in Medicine. 2001; 3:2: 139-147.

8 Prothrombin (G20210A) Gene Polymorphism (PTG G20210A); http://pathology.mc.duke.edu/coag/PTGflyer2.html.

9 Dumas T, Hawke TL, Lee CR. Warfarin Dosing and the Promise of Pharmacogenomics. Curr Clin Pharmacology 2007;2(1): 11-21.

10 Wadeius M. POINT-Pro: Use of Pharmacogenetics in Guiding Treatment with Warfarin. Clin Chem. 2009;55(4): 1-3.

11 Limdi et al (2009). Influence of CYP2C9 and VKORC1 or Warfarin Response During Initiation of Therapy. Blood Cells Mol. Dis. 2009 Jul-Aug:43(1):119.